Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# BroadOak Capital Partners

Investing and Advisory solutions for life sciences businesses.

## Sitemaps

- [XML Sitemap](https://broadoak.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Quartzy Announces $23 Million Financing from Avenue Capital Group and BroadOak Capital Partners](https://www.businesswire.com/news/home/20260413482610/en/Quartzy-Announces-$23-Million-Financing-from-Avenue-Capital-Group-and-BroadOak-Capital-Partners#new_tab) - HAYWARD, Calif.--(BUSINESS WIRE)--Quartzy, a vertically-integrated procurement platform for the life sciences industry, announced it has secured $23 million in financing from Avenue Capital Group and BroadOak Capital Partners.
- [Harvard Bioscience Announces Successful Completion of Debt Refinancing](https://broadoak.com/harvard-bioscience-announces-successful-completion-of-debt-refinancing/) - BroadOak Capital Partners is proud to support Harvard Bioscience through a comprehensive $40 million growth financing package that strengthens the company’s balance sheet and positions it for long-term success. This strategic partnership underscores BroadOak’s commitment to empowering life sciences innovators with flexible capital solutions that drive value and accelerate progress. HOLLISTON, Mass., Dec. 17, 2025
- [BroadOak Capital Partners Adds More Than $200 Million of Permanent Capital to Supplement Investment Platform](https://broadoak.com/broadoak-capital-partners-adds-more-than-200-million-of-permanent-capital-to-supplement-investment-platform/) - Evergreen capital base enables BroadOak to pursue its life sciences growth capital strategy over a longer horizon of investment cycles and to be opportunistic in special situations. BETHESDA, Md.–(BUSINESS WIRE)–BroadOak Capital Partners (“BroadOak”), a life science focused investment and advisory firm, announced it has added over $200 million of permanent capital to its investing platform,
- [Codis Raises Growth Capital to Expand Commercial Manufacturing; Welcomes 1315 Capital](https://broadoak.com/codis-raises-growth-capital-to-expand-commercial-manufacturing-welcomes-1315-capital/) - BroadOak Capital Partners is proud to support Codis, building on the company’s scale, quality, and global reach. The full press release is below. ST. LOUIS, Oct. 16, 2025 /PRNewswire/ — Codis, a CDMO focused on commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, today announced a growth investment from 1315 Capital, with participation from
- [Codis Launches as Global CDMO for Commercial Spray Drying and Amorphous Solid Dispersions](https://broadoak.com/codis-launches-as-global-cdmo-for-commercial-spray-drying-and-amorphous-solid-dispersions/) - BroadOak Capital Partners is an investor in Codis – formerly Particle Dynamics. The full press release is below. ST. LOUIS, Oct. 14, 2025 /PRNewswire/ — Codis officially launches as a new global CDMO specializing in commercial-scale spray drying, amorphous solid dispersions (ASD), and particle engineering technologies. Formed through the integration of Particle Dynamics in the US
- [Battery Ventures Completes Take-Private Transaction with Enzo Biochem](https://broadoak.com/battery-ventures-completes-take-private-transaction-with-enzo-biochem/) - BroadOak Capital Partners advised the Board of Directors of Enzo Biochem on strategic alternatives and the take-private transaction by Battery Ventures. The full press release is below. BOSTON–Battery Ventures, a global, technology-focused investment firm, announced the completion of its take-private of Enzo Biochem (“Enzo”), a life-science research reagents company. Enzo offers over 200,000 research
- [Scientific Industries completes the divestiture of its Genie division to Troemner, a subsidiary of Mettler-Toledo](https://broadoak.com/scientific-industries-completes-the-divestiture-of-its-genie-division-to-troemner-a-subsidiary-of-mettler-toledo/) - BroadOak Capital Partners advised Scientific Industries on the divestiture of its Genie division. The full press release is below. BOHEMIA, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) — Scientific Industries Inc. (OTCQB: SCND) (the “Company”) announced that it has sold its Genie Division to Troemner, LLC, a manufacturing sister company of OHAUS Corporation, (the “Buyer”) for
- [Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations](https://broadoak.com/pluristyx-completes-investment-round-to-expand-product-portfolio-and-commercial-operations/) - We’re pleased to share that Pluristyx, a BroadOak Capital Partners portfolio company, has recently completed an investment round to expand inventory with new clinical grade cell lines. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. The full press release is below. Seattle, Washington: July
- [Particle Dynamics acquires EuroAPI UK](https://broadoak.com/particle-dynamics-acquires-euroapi-uk-a-commercial-spray-drying-facility-in-haverhill-uk/) - We’re pleased to share that Particle Dynamics, a BroadOak Capital Partners portfolio company, has acquired EuroAPI UK Ltd., a commercial spray drying facility in Haverhill, UK. This acquisition expands Particle Dynamics’ global GMP-compliant manufacturing capacity and strengthens their position as a leading CDMO to meet growing demand for improved bioavailability, solubility and stability of therapeutic
- [Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio](https://broadoak.com/waters-acquires-halo-labs-expanding-biological-analysis-portfolio/) - BroadOak Capital Partners is pleased to share that Halo Labs has been acquired by Waters Corporation. BroadOak has supported Halo Labs for years as the company grew. This acquisition is a powerful validation of Halo’s vision, team, and technology. It also reflects the growing demand for advanced analytical tools that ensure safety and quality in
- [Rubicon Founders Invests in Horizon Infusions](https://broadoak.com/rubicon-founders-invests-in-horizon-infusions/) - BroadOak Capital Partners is pleased to share that Rubicon Founders has invested in Horizon Infusions. BroadOak has supported Horizon Infusions for several years as the company grew from a single location to nearly two-dozen. With increased interest and support, Horizon Infusions’ excellent team and business model will continue to scale to meet growing customer demand.
- [Werfen acquires Omixon](https://broadoak.com/werfen-acquires-omixon/) - BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics. The full press release is below. October 16, 2024 (Barcelona, Spain): Werfen announced today that it has completed the acquisition of Omixon after obtaining all
- [PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line](https://broadoak.com/pak-biosolutions-raises-12-million-series-a-to-expand-continuous-biomanufacturing-product-line/) - BroadOak Capital Partners invested in PAK Biosolutions to expand their commercial and product development. The full press release is below. Vienna, VA: Today, PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems
- [ZoBio Sells to Oncodesign Services](https://broadoak.com/zobio-sells-to-oncodesign-services/) - BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services. ZoBio is a leading provider of biophysics-based small molecule drug discovery services. The full press release is below. Dijon, France & Leiden, The Netherlands, January 23rd, 2024 – Oncodesign Services (ODS), a leading Contract Research Organization specialized in drug discovery and
- [LabConnect Acquires A4P Bio](https://broadoak.com/labconnect-acquires-a4p-bio/) - BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions and consultancy for clinical trials. The full press release is below. JOHNSON CITY, Tenn., April 22, 2024 /PRNewswire/ — LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific consultancy company, specializing in bioanalytical and biosample project
- [Pluristyx Closes Major Fundraising Round](https://broadoak.com/pluristyx-closes-major-fundraising-round/) - BroadOak Capital Partners led Pluristyx’s latest fundraising round, which featured participation from existing investors and key opinion leaders in the life sciences sector. The full press release is below. SEATTLE, WA – December 21, 2023 – Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing
- [celares GmbH Sells to Biosynth](https://broadoak.com/celares-gmbh-sells-to-biosynth/) - BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions for Pharma and IVD industries. The full press release is below. Staad, 11th July 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader
- [Genomenon Acquires Boston Genetics](https://broadoak.com/genomenon-acquires-boston-genetics/) - Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics interpretation and curation company. The full press release is below. Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge
- [Indee Labs Investment from BroadOak BioTools Venture Fund](https://broadoak.com/indee-labs-investment-from-broadoak-biotools-venture-fund/) - BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint. DeciBio Consulting, a boutique life science strategy consulting firm, partnered with BroadOak
- [Sanguine Biosciences Partners with BroadOak](https://broadoak.com/sanguine-biosciences-partners-with-broadoak/) - Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine and cell & gene therapy R&D. Our investment will help Sanguine expand laboratory operations, leukapheresis offerings, and their patient donor network. The full press release is below. WALTHAM, Mass., Jan. 9, 2023 /PRNewswire/ — Sanguine Biosciences (“Sanguine”), a leader
- [BroadOak Invests in CDI Laboratories](https://broadoak.com/broadoak-invests-in-cdi-laboratories/) - BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below. BALTIMORE, Jan. 9, 2023 /PRNewswire/ — CDI Laboratories, Inc (“CDI Labs”) announced today that it has received a significant investment from BroadOak Capital Partners (“BroadOak”)
- [PBS Biotech Raises $22M](https://broadoak.com/pbs-biotech-raises-22m/) - BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million financing that will be used to improve the company’s products portfolio, expand its process development services capability, and increase customer support for global cell therapy clients. The full press release is below. CAMARILLO, Calif., Jan. 9, 2023 /PRNewswire/ — PBS Biotech
- [FujiFilm Invests in PhenoVista Biosciences](https://broadoak.com/fujifilm-invests-in-phenovista-biosciences/) - BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services, received an investment from Fujifilm’s Life Sciences Corporate Venture Capital Fund to accelerate development of new high-content screening assay services using differentiated iPSCs. The full press release is below. TOKYO, December 14, 2022 – FUJIFILM Corporation (President and CEO,
- [BioCare Medical Acquires Empire Genomics](https://broadoak.com/biocare-medical-acquires-empire-genomics/) - BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, acquired BroadOak portfolio company Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics. The transaction brings an expansive molecular product suite and custom genomic biomarker development capabilities to BioCare. The
- [BroadOak Invests in EmVenio Research](https://broadoak.com/broadoak-invests-in-emvenio-research/) - BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team in September 2022. EmVenio Research is a Decentralized Clinical Trials (DCT) company originally launched as part of Matrix Medical Network in 2020. In 2022, the company was spun out and recapitalized by its management team. EmVenio provides DCT operational
- [BroadOak Partners with United Biochannels to Acquire ORFLO Technologies](https://broadoak.com/broadoak-partners-with-united-biochannels-to-acquire-orflo-technologies/) - BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a leading manufacturer of cell counting and characterization technologies, will be led by Varshal Davé, UBC’s Managing Partner, who will assume the role of Chief Executive Officer. With over 3,000 instruments installed worldwide, ORFLO has a strong market presence and
- [Flagship Biosciences hires Tom Turi, Ph.D. as CSO](https://broadoak.com/flagship-biosciences-hires-tom-turi-ph-d-as-cso/) - Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the company’s spatial biology and biomarker analytics business and expand strategic partnerships supporting customers’ therapeutic development and clinical trials needs. BroadOak recently provided growth equity funding to Flagship Biosciences. Flagship’s full press release is below. BROOMFIELD, Colo., September 27, 2022—Flagship
- [Flagship Acquires Interpace’s Pharma Services Business](https://broadoak.com/flagship-acquires-interpace/) - Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a provider of cytogenetic, molecular pathology, and genomic profiling solutions. Bill Snider and Aaron Fisher are joining the Board of Flagship Biosciences. The full press release is below. BROOMFIELD, Colo., Aug. 31, 2022 /PRNewswire/ — Flagship Biosciences, Inc., a leader
- [BroadOak Invests in Kemp Proteins](https://broadoak.com/broadoak-invests-in-kemp-proteins/) - BroadOak invested in Kemp Proteins, a leading CDMO specializing in the production of novel proteins. The investment will be used to expand Kemp Proteins’ bacteria expression and plasmid production services in Frederick, Maryland. The full press release is below. Kemp Proteins Secures $5M Growth Financing from BroadOak Capital Partners Funding for expansion of facilities to
- [BroadOak Increases Investment in Halo Labs](https://broadoak.com/broadoak-increases-investment-in-halo-labs/) - BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment in Halo Labs as part of the company’s Series C round of growth financing. Halo Labs uses state-of-the-art optics and image processing to support drug development. The funding will help Halo Labs grow its product and solutions portfolio for
- [BroadOak Invests in Microsize](https://broadoak.com/broadoak-invests-in-microsize/) - BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of its launch as an independent business. The full press release is below. Microsize Launched as Independent Pharma Services Company Meets the Growing Need for US-Based API Solubility and Bioavailability Enhancement Services QUAKERTOWN, Pa. — Microsize today announced the launch
- [Biosynth Carbosynth Acquires Aalto Bio Reagents](https://broadoak.com/biosynth-carbosynth-acquires-aalto-bio-reagents/) - BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 – Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to
- [Biolog Announces New Leadership Team and Investment](https://broadoak.com/biolog-announces-new-leadership-team-and-investment/) - BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification and phenotypic profiling technologies. Operating Partner Robert Wicke will serve as CEO of Biolog. Bill Snider and Robert Wicke will also serve on the company’s Board of Directors. The full press release is below. Biolog Announces New Leadership Team
- [BroadOak Q1 2022 M&A Newsletter](https://broadoak.com/broadoak-q1-2022-ma-newsletter/) - BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 1Q 2022 BroadOak M&A Newsletter.
- [BRT Sells to Medix Biochemica](https://broadoak.com/brt-sells-to-medix-biochemica/) - BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry. The full press release is below. Bioresource Technology joins Medix Biochemica Group Medix Biochemica broadens its capabilities in diagnostic base matrices
- [BroadOak Announces Investment in LabVoice](https://broadoak.com/broadoak-announces-investment-in-labvoice/) - BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create proven efficiencies for customers. Newly commercial, the company has already
- [BroadOak Q4 2021 M&A Newsletter](https://broadoak.com/broadoak-q4-2021-ma-newsletter/) - BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter.
- [Reaction Biology Acquired by Cobepa](https://broadoak.com/reaction-biology-acquired-by-cobepa/) - BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction’s capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies, and an extensive array of cell-based assays. Reaction maintains one
- [Rockland Acquires Antibodies-Online](https://broadoak.com/rockland-immunochemicals-acquires-antibodies-online/) - Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: “We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland is a highly respected and innovative business that has
- [KCAS Acquires FlowMetric](https://broadoak.com/kcas-acquires-flowmetric/) - BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners portfolio Company, announces acquisition
- [Genomenon Raises $20M Series B Financing](https://broadoak.com/genomenon-raises-20m-series-b-financing/) - BroadOak increased its investment in Genomenon, a company that organizes the world’s genomic data. The full press release is below. Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data Financing led by Beringea and Spring Mountain Capital to fuel continued growth in pharmaceutical and clinical diagnostic markets Genomenon®Inc., an AI-driven
- [MyChem Sells To Maravai LifeSciences](https://broadoak.com/mychem-sells-to-maravai-lifesciences/) - BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities
- [BroadOak Leads Acquisition of Particle Dynamics](https://broadoak.com/broadoak-leads-acquisition-of-particle-dynamics/) - An investor group led by BroadOak Capital Partners acquired Particle Dynamics from Edgewater Capital Partners. Particle Dynamics is a global leader in particle processing, delivery technologies, and finished dose manufacturing for the pharmaceutical, over-the-counter, and nutraceutical markets. The full press release is below. Particle Dynamics Announces Sale to New Ownership Group Led by BroadOak Capital
- [Nanosyn Sells to Element Materials Technology](https://broadoak.com/nanosyn-sells-to-element-materials-technology/) - BroadOak Partners advises Nanosyn on the sale of the company to Element Materials Technology (“Element”). Nanoysn is a full-service drug discovery CDMO that provides chemistry, biology, API, and formulation services to pharmaceutical companies. The full press release is below. Element further bolsters its pharmaceuticals offering with Nanosyn acquisition London, UK – October 11, 2021 –
- [BroadOak Provides $8M Loan to Interpace Biosciences](https://broadoak.com/broadoak-provides-8m-loan-to-interpace-biosciences/) - BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The full press release is
- [JMI Announces Sale to Element Materials Technology](https://broadoak.com/jmi-announces-sale-to-element-materials-technology/) - BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element strengthens pharmaceutical and biotech capability with JMI Laboratories
- [Bryan Poltilove Joins BroadOak Capital Partners Team](https://broadoak.com/bryan-poltilove-joins-broadoak-capital-partners-team/) - BroadOak Capital Partners is pleased to announce the addition of Bryan Poltilove to its growth capital investing team, where he serves as a Managing Director. Mr. Poltilove joins BroadOak from Thermo Fisher Scientific and brings with him significant domain and operational expertise. Most recently as a Vice President at Thermo Fisher, Mr. Poltilove built and
- [KCAS Sells To Vitruvian](https://broadoak.com/kcas-sells-to-vitruvian/) - BroadOak Capital Partners advised KCAS Bioanalytical and Biomarker Services (“KCAS”) on the sale of the company to Vitruvian. KCAS is a leading contract research organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries. The full press release is below. Vitruvian Partners announces strategic growth investment in
- [PBS Biotech Raises $10M in Growth Capital](https://broadoak.com/pbs-biotech-raises-10m-to-provide-scale-up-manufacturing-solutions-for-cell-therapies/) - Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services. The full press release is below. PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies
- [Vigene Biosciences Acquired by Charles River Laboratories](https://broadoak.com/vigene-biosciences-acquired-by-charles-river-laboratories/) - BroadOak portfolio company Vigene Biosciences was acquired by Charles River Laboratories. Vigene Biosciences is a leading CDMO providing viral vector manufacturing services for the cell and gene therapy market. The full press release is below. Charles River Laboratories Completes Acquisition of Vigene Biosciences WILMINGTON, Mass.–(BUSINESS WIRE)–Jun. 29, 2021– Charles River Laboratories International, Inc. (NYSE: CRL)
- [Kromatid Receives $2M Investment From BroadOak Capital Partners](https://broadoak.com/kromatid-receives-2m-investment-from-broadoak-capital-partners/) - BroadOak Capital Partners invested growth capital in KromaTiD. KromaTiD sells structural genomic products and tech-enabled services to optimize gene editing for research and clinical purposes. The funding will help accelerate the commercialization of its recently launched direction genomic hybridization In-Site and SCREEN products for gene editing and gene therapy applications. The full press release is
- [BroadOak Leads Investment In Genomenon](https://broadoak.com/broadoak-leads-investment-in-genomenon/) - Genomenon announced that it has completed a $5.3M financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. The full press release is below. Genomenon Completes $5.3M Financing RoundAI-Driven Genomics Company Uses Investment to Fuel Commercial Expansion Genomenon announced
- [Distributed Bio Acquired By Charles River Laboratories](https://broadoak.com/distributed-bio-acquired-by-charles-river-laboratories/) - BroadOak portfolio company Distributed Bio was acquired by Charles River Laboratories. Distributed Bio is a provider of innovative antibody discovery, engineering, informatics tools, and services for the life sciences research and drug discovery markets. The full press release is below. Charles River Laboratories Acquires Distributed Bio – Establishes a Premier, Integrated, Large Molecule Discovery Platform
- [InFuse Holdings Closes Series A Financing And Acquires Horizon Infusions](https://broadoak.com/infuse-holdings-closes-series-a-financing-and-acquires-horizon-infusions/) - BroadOak leads the formation and funding of a new ambulatory infusion platform, InFuse Holdings, to build a network of infusion centers throughout the Midwest. Initial funding used to acquire Cincinnati-based Horizon Infusions and provide growth capital for its expansion. The full press release is below. InFuse Holdings Closes Series A Financing and Acquires Horizon Infusions,
- [Akron Biotech Acquired By Arcline Investment Management](https://broadoak.com/akron-biotech-acquired-by-arcline-investment-management/) - BroadOak portfolio company Akron Biotech was acquired by Arcline Investment Management. Akron is a provider of GMP-compliant cell-/gene-therapy and engineered tissue products and services. The full press release is below. Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology BOCA RATON, Fla., Sept. 11, 2019 /PRNewswire/ — Arcline Investment
- [Cenetron Sells To Versiti](https://broadoak.com/cenetron-sells-to-versiti/) - BroadOak Partners advised Cenetron Diagnostics (“Cenetron”) on the sale of the company to Versiti. Cenetron provides central laboratory services to support global clinical trials for biopharmaceutical, diagnostic, and contract research organizations. The full press release is below. Versiti Acquires Texas-based Cenetron Central Laboratories and Salus IRB to Advance Clinical Trial Capabilities Milwaukee, Wis., – July
- [Astero Bio Sells To BioLife Solutions](https://broadoak.com/astero-bio-sells-to-biolife-solutions/) - BroadOak Capital Partners advised Astero Bio Corporation (“Astero”) on the sale of the company to BioLife Solutions. Astero is a provider of innovative tools that improve the quality of high-value cell and gene therapies. The full press release is below. BioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio Gains
- [Reaction Biology Acquires ProQinase GmbH](https://broadoak.com/reaction-biology-acquires-proqinase-gmbh/) - Reaction Biology Corporation (“RBC”), a BroadOak portfolio company, completes a stock swap transaction whereby RBC acquires all the shares of ProQinase GmbH, an early stage drug discovery company based in Freiburg, Germany. RBC is an early stage drug discovery CRO specializing in biochemical and cell-based assay services. The full press release is below. Reaction Biology
- [Distributed Bio Partners With Charles River Laboratories](https://broadoak.com/distributed-bio-enters-into-exclusive-partnership-with-charles-river-laboratories/) - Distributed Bio, a BroadOak portfolio company, provided Charles River Laboratories’ clients access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies. Distributed Bio is a provider of antibody discovery, engineering, informatics tools, and services for the life sciences research and drug discovery markets. The full press release is below. Charles River and Distributed Bio
- [DANI Instruments Sells To PerkinElmer](https://broadoak.com/dani-instruments-sells-to-perkinelmer/) - BroadOak Partners advises DANI Instruments (“DANI”) on its sale to PerkinElmer. DANI is a provider of advanced gas chromatography instruments and systems for food analysis, pharmaceutical, and environmental applications. The full story is below. PerkinElmer Revenues Grow 22 Percent, Diagnostics Up 59 Percent NEW YORK (GenomeWeb) – PerkinElmer said after the close of the market
- [LifeSpan Biosciences Sells To Thompson Street](https://broadoak.com/lifespan-biosciences-sells-to-thompson-street/) - BroadOak Partners advises LifeSpan Biosciences (“LSBio”) on the sale of the company to Thompson Street Capital Partners. LSBio provides antibodies and life science reagents to the academic and pharmaceutical research markets through its proprietary e-commerce platform. The full press release is below. Thompson Street Capital Partners Acquires LifeSpan Biosciences, Inc. ST. LOUIS–(BUSINESS WIRE)–Thompson Street Capital
- [Astero Bio Acquires Key Assets From MedCision](https://broadoak.com/astero-bio-acquires-key-assets-from-medcision/) - BroadOak-backed Astero Bio, a leading developer of biologics cryopreservation solutions, acquires key assets and rights related to MedCision, LLC’s ThawSTAR cell thawing system and BioT cold storage and transport solutions. The full press release is below. Astero Bio Acquires Key Technologies for the Management of Cryopreserved Biologics from BroadOak Capital Partners MENLO PARK, Calif.–(BUSINESS WIRE)–Astero
- [Lucigen Sells To LGC](https://broadoak.com/lucigen-sells-to-lgc/) - BroadOak Partners advises Lucigen Corporation on the sale of the company to LGC Limited. Lucigen is a leading provider of molecular biology enzymes, reagents, and kits for high growth applications in clinical diagnostics, drug discovery, synthetic biology, and gene editing. The full press release is below. LGC acquires Lucigen, strengthening its reagents offering to the
- [BioInformatics Acquires IMV Publishing](https://broadoak.com/bioinformatics-acquires-imv-publishing/) - BioInformatics, a BroadOak portfolio company, acquired IMV Publishing, a leading market research and online publishing business focused on the medical imaging and clinical diagnostic instruments markets. The full story is below. BioInformatics Inc. Acquires IMV Publishing March 13, 2018: BioInformatics Inc., the leading market research firm supporting the analytical instrumentation and life science industries, and
- [BioInformatics Acquires Kalorama Information](https://broadoak.com/bioinformatics-acquires-kalorama-information/) - BioInformatics, a BroadOak portfolio company, acquires Kalorama Information, a leading market research publisher focused on the in vitro diagnostics, biotechnology, healthcare, medical device, and pharmaceutical markets. The full press release is below. BioInformatics Inc. Acquires Kalorama Information, Further Solidifying a Leadership Position in the Life Science, Diagnostics, and Imaging Markets ARLINGTON, VA. (PRWEB) NOVEMBER 01,

## Pages

- [Home](https://broadoak.com/) - BroadOak Capital Partners is a boutique financial institution providing direct investment and banking services to life sciences and biopharma services companies
- [Team](https://broadoak.com/about/team/) - Our Team Experienced, Deep Networks, Committed to Clients All INVESTMENT TEAM ADVISORY TEAM Bill SniderPartner Bill leads the firm’s growth capital investing activities. VIEW FULL BIO D. Kyle WilsonPartner Kyle leads the firm’s M&A advisory activities and has 25 years of investment banking experience. VIEW FULL BIO Tim JohnsonPartner Tim has over 25 years of M&A,
- [Portfolio](https://broadoak.com/investing/portfolio/) - Our Portfolio Companies Relationship Based. Authentic Partnership. Common Goals. Across our investing and advisory functions, BroadOak has partnered with more than 120 life sciences companies over the last 15 years with industry-leading results. Meet our portfolio companies. All ACTIVE EXITED BroadOak knows the life sciences tools and services industry inside and out. From start to
- [Calvin Aubrey](https://broadoak.com/about/team/calvin-aubrey/) - BACK TO TEAM INVESTMENT Calvin Aubrey Vice President Calvin Aubrey is a Vice President on BroadOak’s growth capital investing team where he specializes in portfolio management and investment execution. Prior to joining BroadOak in 2025, Calvin worked for ARCHIMED where he focused on life sciences, pharmaceutical services, and medical devices investing, and for the Healthcare
- [Investing](https://broadoak.com/investing/) - Investing We bring the power of our platform, connections and experience to every investment and enjoy backing teams and businesses that are generally misunderstood or overlooked by the broader market. Our Investment Approach BroadOak Asset Management was founded to address the capital needs of underserved, growth-stage life sciences companies. Many next-generation technologies start their development
- [Tim Johnson](https://broadoak.com/about/team/tim-johnson/) - BACK TO TEAM INVESTMENT Tim Johnson Partner Tim Johnson is a Partner at BroadOak Capital with more than 25 years of experience in M&A, private equity, and operating leadership. He currently serves as Chairman of LabConnect, Inc. and was recently the co-founder and CEO of Horizon Infusions. His recent board roles include LabConnect, Science and Medicine
- [Bill Snider](https://broadoak.com/about/team/bill-snider/) - BACK TO TEAM INVESTMENT Bill Snider Partner Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 20 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC, a life sciences focused venture capital firm.
- [Daniel Friedman](https://broadoak.com/about/team/daniel-friedman/) - BACK TO TEAM INVESTMENT Daniel Friedman Managing Director Daniel Friedman Daniel Friedman is a Managing Director on BroadOak’s growth capital investing team where he specializes in portfolio management and investment execution. Prior to joining BroadOak in 2019, Daniel worked for Raymond James within the Life Sciences Investment Banking team where he focused on public financings and
- [Michael Caspani](https://broadoak.com/about/team/michael-caspani/) - BACK TO TEAM INVESTMENT Michael Caspani Managing Director Michael Caspani is a Managing Director and helps lead evaluation, execution, and portfolio management efforts for the firm’s debt and equity investments. Prior to joining BroadOak as a Vice President in 2017, he was a credit analyst at Macquarie Group, and before that an investment banker at
- [Contact](https://broadoak.com/contact/) - Get In Touch Thank you for your interest in BroadOak Capital Partners. Getting in touch with us is easy. Just fill out the form based on your request, and we will respond as soon as possible. Inquiries Entrepreneur Inquiry If you’re an entrepreneur interested in talking about our services, please select the Entrepreneur Inquiry option.
- [Transactions](https://broadoak.com/advisory/transactions/) - Advisory Transactions Relationship Based. Authentic Partnership. Common Goals. Take-private sale of the company to Battery Ventures Sale of its Genie Division to Troemner, LLC, a subsidiary of Mettler-Toledo Sale of the company to Werfen Acquisition of A4P Bio Sale of the company to Oncodesign Services Acquistion of celares GmBH Sale of the company to
- [Advisory](https://broadoak.com/advisory/) - Investment Banking Advisory Objective Advice, Industry Expertise, Trusted Partner BroadOak Partners' Strengths BroadOak Partners has successfully completed more than 50 life sciences-related engagements over our 15-year history. Our investment banking advisory practice through BroadOak Partners provides a comprehensive range of services with objective and actionable advice. Objective Advice Our advice and transaction guidance are based
- [Expertise and Industry Engagement](https://broadoak.com/investing/expertise/) - Expertise Key Opinion Leader Engagement. Thought Leadership. Our Industry Knowledge Looking to the future, emerging life sciences technologies will drive the industry, enabling a new wave of scientific understanding and therapies developed for patients with conditions once thought impossible to treat. With an eye toward the future of life sciences technology, BroadOak has built a
- [Lars Hanan](https://broadoak.com/about/team/lars-hanan/) - BACK TO TEAM ADVISORY Lars Hanan Partner Lars Hanan is Partner at BroadOak. For over 25 years Lars has been providing M&A advice to life sciences companies. Prior to BroadOak, Lars built and managed the life sciences advisory business at Mercator Capital. Before joining Mercator Lars headed the M&A Group at ABN AMRO Investment Banking.
- [Matt McFarland](https://broadoak.com/about/team/matt-mcfarland/) - BACK TO TEAM ADVISORY Matt McFarland Partner Matt McFarland is a Partner at BroadOak. He has over 15 years of investment banking and corporate finance experience. Prior to joining BroadOak, he worked for Morgan Stanley’s Capital Strategies Group, an investment banking division focused on middle-market mergers and acquisitions. At Morgan Stanley, Matt was responsible for a variety
- [About](https://broadoak.com/about/) - About Objective Advice, Industry Expertise, Trusted Partner Our Story BroadOak Capital Partners was founded in 2006 by Bill Snider and Lars Hanan with the goal of providing growth capital and advisory services to life sciences companies that are underserved or overlooked by traditional financial services providers. Today, BroadOak Capital Partners is the industry’s most active
- [Trent Carrier](https://broadoak.com/about/team/trent-carrier/) - BACK TO TEAM INVESTMENT Trent Carrier Operating Partner Trent Carrier is an Operating Partner at BroadOak and works with portfolio companies to streamline and scale operations in addition to supporting the firm’s capital investment activities in bioprocessing tools and services companies. Prior to BroadOak, Trent held executive positions in L7 Informatics, Cytosen Therapeutics, and Biologics
- [BioTools Venture Fund](https://broadoak.com/biotools-venture-fund/) - BioTools Venture Fund We bring the power of our platform, connections and experience to every investment and enjoy backing teams and businesses that are generally misunderstood or overlooked by the broader market. Launched in collaboration with DeciBio in October 2022, the BroadOak BioTools Venture Fund provides early stage growth capital to promising young companies. With a
- [Anup Parikh](https://broadoak.com/about/team/anup-parikh/) - BACK TO TEAM INVESTMENT Anup Parikh Operating Partner Anup Parikh is an Operating Partner at BroadOak and helps lead the firm’s capital investing activities focused on companies operating within the molecular biology and software segments. Anup has more than 10 years of experience leading complex hardware, reagent and software product strategy and development. Previously, he
- [BioTools](https://broadoak.com/investing/biotools/) - BioTools Innovator Supporting Entrepreneurs. Investing in the Future. BroadOak is a founding sponsor of BioTools Innovator, the premier accelerator for life sciences research tools companies. Based in Los Angeles, California, BioTools Innovator matches industry leaders with innovative early-stage and emerging growth biotechnology-focused companies for mentorship and support. Many early-stage companies have an excellent team and
- [Max Weis](https://broadoak.com/about/team/max-weis/) - BACK TO TEAM INVESTMENT Max Weis Associate Max Weis is an Associate at BroadOak, where he specializes in portfolio management and investment execution as part of BroadOak’s growth capital investing team. Prior to joining BroadOak in 2024, Max worked as a Valuation Analyst for MPA Consulting, a boutique firm focused on advisory services in the
- [Aaron Goldman](https://broadoak.com/about/team/aaron-goldman/) - BACK TO TEAM INVESTMENT Aaron Goldman Operating Partner Aaron is an Operating Partner at BroadOak where he supports the firm’s investing activities, diligence, and portfolio companies focused on complex biological models and cell therapy. Prior to BroadOak, Aaron held senior positions at clinical-stage therapeutics companies and led product development R&D at several biotools companies focused
- [Austin Duke](https://broadoak.com/about/team/austin-duke/) - BACK TO TEAM INVESTMENT Austin Duke Managing Director Austin Duke is a Managing Director at BroadOak where he primarily leads and supports the firm’s venture capital and early-stage investments. Prior to joining BroadOak, Austin led healthcare venture capital investments for UnityPoint Health Ventures. He has led investments and served on the board of directors for
- [Pete Corish](https://broadoak.com/about/team/pete-corish/) - BACK TO TEAM ADVISORY Pete Corish Vice President of Business Development, Europe Pete Corish is BroadOak’s VP Business Development in Europe, expanding the recognition of, and access to, BroadOak’s expertise, capabilities and services to European Life Science companies and investors. With 20 years of experience in core clinical laboratory, Point-of-Care immunoassay, and molecular diagnostics markets,
- [Henry Dervishi](https://broadoak.com/about/team/henry-dervishi/) - BACK TO TEAM INVESTMENT Henry Dervishi Associate Henry Dervishi is an Associate at BroadOak, where he specializes in portfolio management and investment execution as part of BroadOak’s growth capital investing team. Prior to joining BroadOak in 2023, Henry worked as an Investment Analyst for Limiar Capital, a DC-based hedge fund where he covered tech and
- [News](https://broadoak.com/news/) - Latest News Updates on BroadOak investments, transactions, events, and industry news. Search Popular Keywords Categories No Record Found View All Results Quartzy Announces $23 Million Financing from Avenue Capital Group and BroadOak Capital Partners Quartzy Announces $23 Million Financing from Avenue Capital Group and BroadOak Capital Partners • April 13, 2026 HAYWARD, Calif.–(BUSINESS WIRE)–Quartzy, a
- [D. Kyle Wilson](https://broadoak.com/about/team/d-kyle-wilson/) - BACK TO TEAM ADVISORY D. Kyle Wilson Partner Kyle Wilson is a Partner at BroadOak and leads the firm’s M&A advisory activities. With over 25 years of investment banking experience, Kyle’s background includes broad transaction experience in both capital formation and mergers and acquisitions. Kyle joined BroadOak in 2011 and built the firm’s San Francisco office. Prior to BroadOak, Kyle was
- [Business Continuity Disclosure](https://broadoak.com/business-continuity/) - Business Continuity Plan BroadOak Partners, LLC and BroadOak Asset Management have developed a Business Continuity Plan (BCP) on how we will respond to events that disrupt our business. Since the timing and impact of the disasters is unpredictable, we will have to be flexible in responding to events as they unfold. We are providing you
- [Holly Atallah](https://broadoak.com/about/team/holly-atallah/) - BACK TO TEAM INVESTMENT Holly Atallah Director of Finance & Operations Holly Atallah is the Director of Finance and Operations for BroadOak. She has almost two decades of investment banking, hedge fund investing and corporate development experience. Prior to joining BroadOak, she was a Vice President for England & Co, a middle market investment bank located in
- [Privacy Policy](https://broadoak.com/privacy/) - Privacy Policy BroadOak Capital Partners is required to disclose its policy for keeping personal information on individual clients under SEC guidelines. These guidelines are oriented toward individual consumer information and the dissemination or sale of that information to third parties. We generally do not possess or collect individual financial information, but we are committed to keeping

## Transactions

- [Sale of BioServices business to Precision Bioservices](https://broadoak.com/transaction/sale-of-bioservices-business-to-precision-bioservices/)
- [Sale of Food Safety and GMO businesses to Romer Labs](https://broadoak.com/transaction/sale-of-food-safety-and-gmo-businesses-to-romer-labs/)
- [Sale of preclinical in-vivo imaging business to Bruker](https://broadoak.com/transaction/sale-of-preclinical-in-vivo-imaging-business-to-bruker/)
- [Exclusive placement agent for OpGen, Inc.](https://broadoak.com/transaction/exclusive-placement-agent-for-opgen-inc/)
- [BroadOak Partners provided financial advisory services to Quanta Biosciences](https://broadoak.com/transaction/broadoak-partners-provided-financial-advisory-services-to-quanta-biosciences/)
- [Non-exclusive license agreement with QIAGEN](https://broadoak.com/transaction/non-exclusive-license-agreement-with-qiagen/)
- [BroadOak retained to provide ongoing financial advisory services](https://broadoak.com/transaction/broadoak-retained-to-provide-ongoing-financial-advisory-services/)
- [SVT gains exclusive rights in China to ENMD-2076 through investment in EntreMed, Inc.](https://broadoak.com/transaction/svt-gains-exclusive-rights-in-china-to-enmd-2076-through-investment-in-entremed-inc/)
- [Replacement and expansion of Cayman Chemical Company’s debt facilities](https://broadoak.com/transaction/replacement-and-expansion-of-cayman-chemical-companys-debt-facilities/)
- [Acquisition of Hyaluron, Inc.](https://broadoak.com/transaction/acquisition-of-hyaluron-inc/)
- [Acquisition of GlobalStem, Inc.](https://broadoak.com/transaction/acquisition-of-globalstem-inc/)
- [Sale of in-vivo preclinical CRO services business to Taconic Farms, Inc.](https://broadoak.com/transaction/sale-of-in-vivo-preclinical-cro-services-business-to-taconic-farms-inc/)
- [Sale of Alpha Innotech Corp. to Cell Biosciences, Inc.](https://broadoak.com/transaction/sale-of-alpha-innotech-corp-to-cell-biosciences-inc/)
- [Collaboration and license agreement with Novartis](https://broadoak.com/transaction/collaboration-and-license-agreement-with-novartis/)
- [Sale of non-core assets to Intrexon Corporation](https://broadoak.com/transaction/sale-of-non-core-assets-to-intrexon-corporation/)
- [Sale of Assay Designs, Inc. to Enzo Biochem, Inc.](https://broadoak.com/transaction/sale-of-assay-designs-inc-to-enzo-biochem-inc/)
- [Sale of Semrock Inc. to IDEX Corp](https://broadoak.com/transaction/sale-of-semrock-inc-to-idex-corp/)
- [Sale of Fluorescent Detection Products Business](https://broadoak.com/transaction/sale-of-fluorescent-detection-products-business/)
- [Acquisition of biodefense vaccines business from Avecia Biologics Limited](https://broadoak.com/transaction/acquisition-of-biodefense-vaccines-business-from-avecia-biologics-limited/)
- [Sale of In Vitro Technologies, Inc to Celsis International Plc](https://broadoak.com/transaction/sale-of-in-vitro-technologies-inc-to-celsis-international-plc/)
- [Acquisition of sales and marketing rights to EpiPen in Canada from Allerex Laboratory](https://broadoak.com/transaction/acquisition-of-sales-and-marketing-rights-to-epipen-in-canada-from-allerex-laboratory/)
- [Acquisition of Control Delivery Systems](https://broadoak.com/transaction/acquisition-of-control-delivery-systems/)
- [Sale of the company to Werfen](https://broadoak.com/transaction/werfen-acquires-omixon/)
- [Sale of NovaScreen Biosciences to Caliper Life Sciences](https://broadoak.com/transaction/sale-of-novascreen-biosciences-to-caliper-life-sciences/)
- [Merger with xantra](https://broadoak.com/transaction/auto-draft-2/)
- [Sale of Sybron Biochemical Division to Novozymes](https://broadoak.com/transaction/auto-draft/)

## Categories

- [News](https://broadoak.com/category/news/)
- [Announcements](https://broadoak.com/category/news/announcements/)
- [Investment News](https://broadoak.com/category/news/investment-news/)
- [Advisory News](https://broadoak.com/category/news/advisory-news/)
- [Newsletter](https://broadoak.com/category/newsletter/)
- [Featured](https://broadoak.com/category/featured/)